Militia Long/Short Equity ETF ORR
39.49 USD +0.01 (+0.03%)
At closeNov 11, 2026, 7:42 PM EST
39.59 +0.10 +0.25%
After hours · Nov 11, 7:42 PM ET
39.43 Day range 39.67
32.44 52-week range 39.80
- YTD
- +15.60%
- 1 year
- +20.84%
News
gurufocus.com Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the n
gurufocus.com RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer RYBREVANT FASPRO⢠(amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced he
gurufocus.com Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer [url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced updated follow-up analyses from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-bispecif
gurufocus.com New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancerPR Newswire
gurufocus.com IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER IMDELLTRAÂ IN COMBINATION WITH IMFINZIÂ REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCERPR NewswireTHOUSAND
gurufocus.com Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026 Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026PR NewswireGUANGZHOU, C
gurufocus.com BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026 [url="]BeOne Medicines Ltd.[/url] (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated inve
gurufocus.com Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026 Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026PR NewswireINDI
gurufocus.com ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast CancerPR NewswireSHANGHAI, O
gurufocus.com /C O R R E C T I O N - AbbVie/ /C O R R E C T I O N - AbbVie/PR NewswireNORTH CHICAGO, Ill., Oct. 18, 2026In the news release, AbbVie to Present Data at the 2026 European Society for Medical
gurufocus.com AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor PortfolioPR News
gurufocus.com Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer [url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced results from Part C of the Phase 1/2 RAINFOLâ¢-01 trial evaluating rinatabart sesutecan (Rina-S), an inv
gurufocus.com Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 [url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of
gurufocus.com Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer Johnson and Johnson's RYBREVANTÂ (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positi
gurufocus.com Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Adv
gurufocus.com Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) [url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously
gurufocus.com New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel New TALVEYÂ (talquetamab-tgvs) plus DARZALEX FASPROÂ (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combi
gurufocus.com BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit [url="]BeOne Medicines Ltd.[/url] (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 datas
gurufocus.com IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Li
seekingalpha.com ORR: A Long/Short Hedge Fund Disguised As An ETF Militia Long/Short Equity ETF offers retail investors access to a diversified, actively managed global long/short equity strategy, typically reserved for hedge funds. ORR's early performance is…